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Résumé en
anglais
UNLABELLED: The aim of this work was to develop an individualized score for
predicting hepatocellular carcinoma (HCC) in patients with hepatitis C (HCV)-
compensated cirrhosis. Among 1,323 patients with HCV cirrhosis enrolled in the
French prospective ANRS CO12 CirVir cohort, 720 and 360 were randomly assigned
to training and validation sets, respectively. Cox's multivariate model was used to
predict HCC, after which a nomogram was computed to assess individualized risk.
During follow-up (median, 51.0 months), 103 and 39 patients developed HCC in the
training and validation sets, respectively. Five variables were independently
associated with occurrence of HCC: age > 50 years (hazard ratio [HR], 1.94; 95%
confidence interval [CI], 1.16; 3.25; P = 0.012); past excessive alcohol intake (HR,
1.55; 95% CI, 1.02; 2.36; P = 0.041); low platelet count (<100 Giga/mm(3) : HR, 2.70;
95% CI, 1.62; 4.51; P < 0.001; [100; 150] Giga/mm(3) : HR, 1.87; 95% CI, 1.10; 3.18; P
= 0.021); gamma-glutamyl transpeptidase above the upper limit of normal (HR, 1.96;
95% CI, 1.11; 3.47; P = 0.021); and absence of a sustained virological response during
follow-up (HR, 3.02; 95% CI, 1.67; 5.48; P < 0.001). An 11-point risk score was derived
from the training cohort and validated in the validation set. Based on this score, the
population was stratified into three groups, in which HCC development gradually
increased, from 0% to 30.1% at 5 years for patients with the lowest (≤3) and highest
(≥8) scores (P < 0.001). Using this score, a nomogram was built enabling
individualized prediction of HCC occurrence at 1, 3, and 5 years.
CONCLUSION: This HCC score can accurately predict HCC at an individual level in
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